Loading...
Home 2019-02-14T13:54:27+00:00

Outlook Therapeutics Provides Business Update and Reports First Quarter Financial Results for Fiscal 2019

Outlook Therapeutics…

…is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a complex, technically challenging and commercially attractive monoclonal antibody, for various ophthalmic indications..

ABOUT ONS-5010

ONS-5010 is a proprietary ophthalmic formulation of bevacizumab to be administered as an intravitreal injection for the treatment of wet AMD and other retina diseases.